
Doo Ho Choi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2645640/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Incidence of BRCA1 and BRCA2 Mutations in Young Korean Breast Cancer Patients. Journal of Clinical Oncology, 2004, 22, 1638-1645.	0.8	97
2	Distribution of <i>BRCA1</i> and <i>BRCA2</i> Mutations in Asian Patients with Breast Cancer. Journal of Breast Cancer, 2013, 16, 357.	0.8	80
3	The Role of Postmastectomy Radiation Therapy After Neoadjuvant Chemotherapy in Clinical Stage II-III Breast Cancer Patients With pN0: A Multicenter, Retrospective Study (KROG 12-05). International Journal of Radiation Oncology Biology Physics, 2014, 88, 65-72.	0.4	67
4	Differences in prognostic factors and patterns of failure between invasive micropapillary carcinoma and invasive ductal carcinoma of the breast: Matched case–control study. Breast, 2010, 19, 231-237.	0.9	57
5	New Technique for Developing a Proton Range Compensator With Use of a 3-Dimensional Printer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 453-458.	0.4	55
6	A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer, 2003, 98, 1587-1595.	2.0	44
7	Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy. Radiation Oncology Journal, 2015, 33, 301.	0.7	44
8	The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study. Familial Cancer, 2013, 12, 75-81.	0.9	43
9	Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer. Breast Cancer Research and Treatment, 2012, 134, 1315-1326.	1.1	42
10	The first private-hospital based proton therapy center in Korea; status of the Proton Therapy Center at Samsung Medical Center. Radiation Oncology Journal, 2015, 33, 337.	0.7	40
11	Metformin enhances the response to radiotherapy in diabetic patients with rectal cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1377-1385.	1.2	40
12	Malignant and borderline phyllodes tumors of the breast: a multicenter study of 362 patients (KROG) Tj ETQq0 () 0 ₁₉ BT /(Dverlock 10 T
13	Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: The Korean Hereditary Breast Cancer (KOHBRA) Study. Breast Cancer Research and Treatment, 2012, 133, 1143-1152.	1.1	38
14	Baseline neutrophil–lymphocyte ratio and platelet–lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy. Tumori, 2019, 105, 434-440.	0.6	36
15	Differences in Prognostic Factors and Failure Patterns Between Invasive Micropapillary Carcinoma and Carcinoma With Micropapillary Component Versus Invasive Ductal Carcinoma of the Breast: Retrospective Multicenter Case–Control Study (KROG 13-06). Clinical Breast Cancer, 2015, 15, 353-361.e2.	1.1	35
16	Patient-reported symptoms of radiation dermatitis during breast cancer radiotherapy: a pilot study. Quality of Life Research, 2017, 26, 1713-1719.	1.5	35

17	The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation. Breast Cancer Research and Treatment, 2008, 112, 569-573.	1.1	28	
	Dosimetric effects of multileaf collimator leaf width on intensitvâ€modulated radiotherapy for head			

18Dosimetric effects of multileaf collimator leaf width on intensityâ€modulated radiotherapy for head
and neck cancer. Medical Physics, 2014, 41, 021712.1.628

#	Article	IF	CITATIONS
19	Unique Characteristics and Failure Patterns of Metaplastic Breast Cancer in Contrast to Invasive Ductal Carcinoma: A Retrospective Multicenter Case–Control Study (KROG 13-07). Clinical Breast Cancer, 2015, 15, e105-e115.	1.1	28
20	Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. Breast Cancer Research and Treatment, 2017, 161, 95-102.	1.1	28
21	Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients. Oncotarget, 2017, 8, 61538-61550.	0.8	28
22	A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients. BMC Cancer, 2014, 14, 645.	1.1	26
23	Immunohistochemical Biomarkers in Patients with Early-Onset Breast Carcinoma by Tissue Microarray. Cancer Journal (Sudbury, Mass), 2005, 11, 404-411.	1.0	25
24	Associations between <i>BRCA</i> Mutations in High-Risk Breast Cancer Patients and Familial Cancers Other than Breast or Ovary. Journal of Breast Cancer, 2012, 15, 283.	0.8	25
25	Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy. Surgery, 2019, 165, 579-585.	1.0	25
26	Association between <i>BRCA</i> Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation. Journal of Breast Cancer, 2013, 16, 308.	0.8	24
27	Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment. Clinical Breast Cancer, 2018, 18, e1141-e1147.	1.1	24
28	Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation. International Journal of Molecular Sciences, 2020, 21, 2691.	1.8	22
29	Acute skin toxicity in Korean breast cancer patients carrying <i>BRCA</i> mutations. International Journal of Radiation Biology, 2014, 90, 90-94.	1.0	21
30	Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: A phase II multi-institutional clinical trial (KROG 11-02). Radiotherapy and Oncology, 2014, 110, 150-154.	0.3	21
31	Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients. Radiation Oncology Journal, 2013, 31, 222.	0.7	21
32	Patterns of Practice in Radiotherapy for Breast Cancer in Korea. Journal of Breast Cancer, 2018, 21, 244.	0.8	20
33	Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23. Cancer Research and Treatment, 2018, 50, 1316-1323.	1.3	20
34	Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes. SpringerPlus, 2013, 2, 136.	1.2	18
35	Outcome of breast-conserving treatment for axillary lymph node metastasis from occult breast cancer with negative breast MRI. Breast, 2020, 49, 63-69.	0.9	18
36	The Breast and Ovarian Cancer Risks in Korea Due to Inherited Mutations in BRCA1 and BRCA2: A Preliminary Report. Journal of Breast Cancer, 2009, 12, 92.	0.8	17

#	Article	IF	CITATIONS
37	Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients. Breast Cancer Research and Treatment, 2012, 131, 217-222.	1.1	17
38	Cyclin D1 is Associated with Radiosensitivity of Triple-Negative Breast Cancer Cells to Proton Beam Irradiation. International Journal of Molecular Sciences, 2019, 20, 4943.	1.8	17
39	Exome sequencing in a breast cancer family without <i>BRCA</i> mutation. Radiation Oncology Journal, 2015, 33, 149.	0.7	17
40	Double Heterozygotes for Non-Caucasian Families with Mutations in BRCA-1 and BRCA-2 Genes. Breast Journal, 2006, 12, 216-220.	0.4	16
41	Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16–12). Breast, 2020, 49, 41-47.	0.9	16
42	Development of patient-specific phantoms for verification of stereotactic body radiation therapy planning in patients with metallic screw fixation. Scientific Reports, 2017, 7, 40922.	1.6	15
43	Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Research and Treatment, 2019, 173, 385-395.	1.1	15
44	Clinical Outcomes of Local Excision Following Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer. Cancer Research and Treatment, 2014, 46, 158-164.	1.3	15
45	Impact of Regional Nodal Irradiation for Breast Cancer Patients with Supraclavicular and/or Internal Mammary Lymph Node Involvement: A Multicenter, Retrospective Study (KROG 16-14). Cancer Research and Treatment, 2019, 51, 1500-1508.	1.3	15
46	The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans. Hereditary Cancer in Clinical Practice, 2019, 17, 1.	0.6	13
47	The Characteristics of Local Recurrence After Breast-Conserving Surgery Alone for Malignant and Borderline Phyllodes Tumors of the Breast (KROG 16-08). Clinical Breast Cancer, 2019, 19, 345-353.e2.	1.1	13
48	The Benefit of Post-Mastectomy Radiotherapy in ypNO Patients after Neoadjuvant Chemotherapy According to Molecular Subtypes. Journal of Breast Cancer, 2019, 22, 285.	0.8	13
49	Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418). Cancer Research and Treatment, 2019, 51, 1041-1051.	1.3	13
50	Comparison of Clinicopathological Features and Treatment Results between Invasive Lobular Carcinoma and Ductal Carcinoma of the Breast. Journal of Breast Cancer, 2015, 18, 285.	0.8	12
51	Prognostic significance of nodal involvement region in clinical stage IIIc breast cancer patients who received primary systemic treatment, surgery, and radiotherapy. Breast, 2015, 24, 637-641.	0.9	12
52	Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 329-336.	0.7	12
53	Optimal radiotherapy for patients with internal mammary lymph node metastasis from breast cancer. Radiation Oncology, 2020, 15, 16.	1.2	12
54	PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations. Breast Cancer Research and Treatment, 2010, 122, 303-306.	1.1	11

#	Article	IF	CITATIONS
55	Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes. Journal of Breast Cancer, 2016, 19, 169.	0.8	11
56	Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418). Cancer Research and Treatment, 2017, 49, 927-936.	1.3	11
57	Excision alone for small size ductal carcinoma in situ of the breast. Breast, 2014, 23, 586-590.	0.9	10
58	Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study. Breast Cancer Research and Treatment, 2021, 189, 167-175.	1.1	10
59	Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. Radiation Oncology Journal, 2016, 34, 34-44.	0.7	10
60	Korean First Prospective Phase II Study, Feasibility of Prone Position in Postoperative Whole Breast Radiotherapy: A Dosimetric Comparison. Cancer Research and Treatment, 2019, 51, 1370-1379.	1.3	10
61	Importance of the Circumferential Extent of Tumors and Clinical Lymph Node Status as Prognostic Factors after Preoperative Chemoradiotherapy and Surgery in Patients with Rectal Cancer. Tumori, 2010, 96, 568-576.	0.6	9
62	HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy. Breast, 2013, 22, 894-897.	0.9	9
63	Influence of boost radiotherapy in patients with ductal carcinoma in situ breast cancer: a multicenter, retrospective study in Korea (KROG 11-04). Breast Cancer Research and Treatment, 2014, 146, 341-345.	1.1	9
64	Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments. Clinical Breast Cancer, 2015, 15, 512-518.	1.1	9
65	Clinical Significance of Mucinous Rectal Adenocarcinoma following Preoperative Chemoradiotherapy and Curative Surgery. Tumori, 2016, 102, 114-121.	0.6	9
66	High-precision quality assurance of robotic couches with six degrees of freedom. Physica Medica, 2018, 49, 28-33.	0.4	9
67	Proton range verification in inhomogeneous tissue: Treatment planning system vs. measurement vs. Monte Carlo simulation. PLoS ONE, 2018, 13, e0193904.	1.1	9
68	Risk factors for locoregional recurrence in patients with pathologic T3N0 rectal cancer with negative resection margin treated by surgery alone. Radiation Oncology Journal, 2019, 37, 110-116.	0.7	9
69	Cervical Lymph Node Involvement above the Supraclavicular Fossa in Breast Cancer: Comparison with Stage IIIC (KROG 18-02). Journal of Breast Cancer, 2020, 23, 194.	0.8	9
70	Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline Plus Taxane-Based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study. Cancer Research and Treatment, 2017, 49, 970-980.	1.3	9
71	The Change of Practice Patterns of the Hereditary Breast Cancer Management in Korea after the Korean Hereditary Breast Cancer Study. Journal of Breast Cancer, 2010, 13, 418.	0.8	8
72	Genetic anticipation of familial breast cancer with or without BRCA mutation in the Korean population. Cancer Genetics, 2014, 207, 160-163.	0.2	8

#	Article	IF	CITATIONS
73	Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?. Journal of Breast Cancer, 2018, 21, 206.	0.8	8
74	Heartâ€sparing radiotherapy with threeâ€dimensional printing technology after mastectomy for patients with left breast cancer. Breast Journal, 2019, 25, 682-686.	0.4	8
75	Prognosis of patients with axillary lymph node metastases from occult breast cancer: analysis of multicenter data. Radiation Oncology Journal, 2021, 39, 107-112.	0.7	8
76	Internal mammary node irradiation in node-positive breast cancer treated with mastectomy and taxane-based chemotherapy. Breast, 2021, 59, 37-43.	0.9	8
77	Analysis of <i>BRIP1</i> Variants among Korean Patients with <i>BRCA1/2</i> Mutation-Negative High-Risk Breast Cancer. Cancer Research and Treatment, 2016, 48, 955-961.	1.3	8
78	Preclinical investigation for developing injectable fiducial markers using a mixture of BaSO ₄ and biodegradable polymer for proton therapy. Medical Physics, 2015, 42, 2626-2637.	1.6	7
79	Prognostic Role of Carcinoembryonic Antigen Level after Preoperative Chemoradiotherapy in Patients with Rectal Cancer. Journal of Gastrointestinal Surgery, 2018, 22, 1772-1778.	0.9	7
80	Clinical Significance of Lymph-Node Ratio in Determining Supraclavicular Lymph-Node Radiation Therapy in pN1 Breast Cancer Patients Who Received Breast-Conserving Treatment (KROG 14-18): A Multicenter Study. Cancers, 2019, 11, 680.	1.7	7
81	Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16). Clinical Breast Cancer, 2019, 19, 78-86.	1.1	7
82	Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study. Scientific Reports, 2021, 11, 8485.	1.6	7
83	Prophylactic Supraclavicular Radiotherapy after Surgery in High-Risk N1 Breast Cancer. Oncology, 2013, 85, 14-20.	0.9	6
84	Development of a 3D optical scanning-based automatic quality assurance system for proton range compensators. Medical Physics, 2015, 42, 1071-1079.	1.6	6
85	A virtual simulator designed for collision prevention in proton therapy. Medical Physics, 2015, 42, 6021-6027.	1.6	6
86	Prognostic Modeling in Pathologic N1 Breast Cancer Without Elective Nodal Irradiation After Current Standard Systemic Management. Clinical Breast Cancer, 2015, 15, e197-e204.	1.1	6
87	Incidental Findings on Simulation CT Images for Adjuvant Radiotherapy in Breast Cancer Patients. Technology in Cancer Research and Treatment, 2015, 14, 525-529.	0.8	6
88	Aggressive Surgical Excision of Supraclavicular Lymph Node Did Not Improve the Outcomes of Breast Cancer With Supraclavicular Lymph Node Involvement (KROG 16-14). Clinical Breast Cancer, 2020, 20, 51-60.	1.1	6
89	Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy. Oncotarget, 2016, 7, 62676-62686.	0.8	6
90	Statistical Errors in Papers Published in the Journal of the Korean Society for Therapeutic Radiology and Oncology. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2008, 26, 289.	0.1	6

#	Article	IF	CITATIONS
91	Can we omit prophylactic inguinal nodal irradiation in anal cancer patients?. Radiation Oncology Journal, 2015, 33, 83.	0.7	6
92	Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer. Journal of Breast Cancer, 2015, 18, 50.	0.8	5
93	Immunohistochemical Detection of p53 Expression in Patients with Preoperative Chemoradiation for Rectal Cancer: Association with Prognosis. Yonsei Medical Journal, 2015, 56, 82.	0.9	5
94	MEASUREMENT OF NEUTRON AMBIENT DOSE EQUIVALENT IN PROTON RADIOTHERAPY WITH LINE-SCANNING AND WOBBLING MODE TREATMENT SYSTEM. Radiation Protection Dosimetry, 2017, 177, 382-388.	0.4	5
95	Selective Radiation Therapy for Ductal Carcinoma <i>In Situ</i> Following Breast-Conserving Surgery According to Age and Margin Width: Korean Radiation Oncology Group 11-04 and 16-02 Studies. Journal of Breast Cancer, 2017, 20, 327.	0.8	5
96	Distribution of tumor subtypes in bilateral breast cancer: Comparison between synchronous and metachronous cancer. Asia-Pacific Journal of Clinical Oncology, 2020, , .	0.7	5
97	New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12). Breast Cancer Research and Treatment, 2021, 186, 453-462.	1.1	5
98	Outcome of radiotherapy for clinically overt metastasis to the internal mammary lymph node in patients receiving neoadjuvant chemotherapy and breast cancer surgery. Breast, 2021, 55, 112-118.	0.9	5
99	Quantitative Changes in Skin Composition Parameters after Radiation Therapy According to Surgery Types Among Patients with Breast Cancer: A Prospective Study. Clinical Breast Cancer, 2022, 22, e224-e231.	1.1	5
100	Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer. Radiation Oncology Journal, 2017, 35, 217-226.	0.7	5
101	Communication with Family Members about Positive BRCA1/2 Genetic Test Results in Korean Hereditary Breast Cancer Families. Journal of Genetic Medicine, 2011, 8, 105-112.	0.1	5
102	Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer. Cancer Research and Treatment, 2020, 52, 446-454.	1.3	5
103	Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG) Tj ETQq1 1 (0. 78 4314	rgBT /Overlo
104	Dosimetric Effects of Intrafractional Organ Motion in Field-in-Field Technique for Whole-Breast Irradiation. Progress in Medical Physics, 2019, 30, 65.	0.5	4
105	Correlation between tumor regression grade and rectal volume in neoadjuvant concurrent chemoradiotherapy for rectal cancer. Radiation Oncology Journal, 2016, 34, 186-192.	0.7	4
106	Heterozygous germline mutations in NBS1 among Korean patients with high-risk breast cancer negative for BRCA1/2 mutation. Familial Cancer, 2015, 14, 365-371.	0.9	3
107	Comparison of failure patterns between tubular breast carcinoma and invasive ductal carcinoma (KROG 14–25). Breast, 2018, 38, 165-170.	0.9	3
108	Gastric Complications after Adjuvant Radiotherapy for Breast Cancer. Journal of Breast Cancer, 2019, 22, 464.	0.8	3

#	Article	IF	CITATIONS
109	Determining whether postoperative chemoradiotherapy is required in patients with pathologic T3N0 rectal cancer with negative resection margin. International Journal of Colorectal Disease, 2020, 35, 2239-2248.	1.0	3
110	Prognostic and predictive value of liver volume in colorectal cancer patients with unresectable liver metastases. Radiation Oncology Journal, 2014, 32, 77.	0.7	3
111	Redefining the Positive Circumferential Resection Margin by Incorporating Preoperative Chemoradiotherapy Treatment Response in Locally Advanced Rectal Cancer: A Multicenter Validation Study. Cancer Research and Treatment, 2018, 50, 506-517.	1.3	3
112	CTNI-05. NRG ONCOLOGY / RTOG 1119: PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY / STEREOTACTIC RADIOSURGERY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASES FROM HER2-POSITIVE BREAST CANCER. Neuro-Oncology, 2020, 22, ii42-ii42.	0.6	3
113	Is higher dose radiation necessary for positive resection margin after breast-conserving surgery for breast cancer?. Breast, 2019, 47, 16-21.	0.9	2
114	Is tumor bed boost necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast conserving therapy? (KROG 12-05 and 16-16). Breast, 2019, 45, 43-47.	0.9	2
115	Germline BRCA Mutation and Clinical Outcomes in Breast Cancer Patients Focusing on Survival and Failure Patterns: A Long-Term Follow-Up Study of Koreans. Medicina (Lithuania), 2020, 56, 514.	0.8	2
116	Impact of Breast Reconstruction on Biophysical Parameters of Mammary Skin in Patients Receiving Postmastectomy Radiotherapy for Breast Cancer. Journal of Breast Cancer, 2021, 24, 206.	0.8	2
117	Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418). Oncotarget, 2017, 8, 1796-1804.	0.8	2
118	A Comparison of Clinical Outcomes for Breast-conserving Treatment and Mastectomy for Early Breast Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2008, 26, 10.	0.1	2
119	Survival and Prognostic Factors for Breast Cancer Patients with Regional Oligo-Recurrence. Journal of Breast Cancer, 2020, 23, 622.	0.8	2
120	Feasibility of using Geant4 Monte Carlo simulation for IMRT dose calculations for the Novalis Tx with a HD-120 multi-leaf collimator. Journal of the Korean Physical Society, 2015, 66, 1489-1494.	0.3	1
121	Limited Supraclavicular Radiation Field in Breast Cancer WithÂ≥ 10 Positive Axillary Lymph Nodes. Clinical Breast Cancer, 2016, 16, e15-e21.	1.1	1
122	Chronological Skin Changes Through Postmastectomy Radiotherapy Based on Radiotherapy Techniques: Using Quantitative Dermatological Measurements. Skin Pharmacology and Physiology, 2021, 34, 229-238.	1.1	1
123	Clinical and dosimetric risk factors for vertebral compression fracture after single-fraction stereotactic body radiation therapy for spine metastases. Journal of Bone Oncology, 2021, 28, 100368.	1.0	1
124	What Is High-risk Breast Cancer With Pathologically Negative Lymph Nodes for Regional Recurrence?. International Journal of Radiation Oncology Biology Physics, 2021, 111, 992-998.	0.4	1
125	Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12). Breast, 2021, 60, 272-278.	0.9	1
126	Immediate breast reconstruction has no impact on the oncologic outcomes of patients treated with post-mastectomy radiation therapy: a comparative analysis based on propensity score matching. Breast Cancer Research and Treatment, 2022, 192, 101-112.	1.1	1

#	Article	IF	CITATIONS
127	Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer. Annals of Surgical Oncology, 2022, , 1.	0.7	1
128	The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12). Cancer Research and Treatment, 2022, 54, 1121-1129.	1.3	1
129	Development of Video Image-Guided Setup (VIGS) System for Tomotherapy: Preliminary Study. Progress in Medical Physics, 2013, 24, 85.	0.4	0
130	Central Nervous System Failure in Korean Breast Cancer Patients with HER2-Enriched Subtype: Korean Radiation Oncology Group 16-15 Multicenter Retrospective Study. Journal of Breast Cancer, 2019, 22, 120.	0.8	0
131	Adjuvant radiation therapy in small ductal carcinoma in situ. Breast, 2019, 43, 55-58.	0.9	0
132	Multicenter study for brain metastasis from breast cancer in Korea: The significance of molecular subtype (Korean Radiation Oncology Group 1612) Journal of Clinical Oncology, 2021, 39, e14008-e14008.	0.8	0
133	Abstract P1-21-01: Multicenter study for brain metastasis from breast cancer in Korea: The significance of molecular subtype (KROG 1612). Cancer Research, 2022, 82, P1-21-01-P1-21-01.	0.4	0
134	ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer. Annals of Surgical Oncology, 2022, , .	0.7	0

9